Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse
17.5.2022 17:00:00 EEST | Business Wire | Press release
Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital, an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005729/en/
LDA Capital lands on Enry's Island, with a € 20M round (Graphic: Business Wire)
“We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster with LDA’s flexible financing package. We are sure that the relationship with LDA will continue in a mutually gratifying way in the medium and long term horizon, allowing the horses in our stable to become unicorns.”
This new capital commitment of funding will be used to scale Enry’s Island phygital capabilities. Specifically, the areas that the company will focus on are:
- Expansion in the Metaverse and physical spaces (thanks to Enry’s Island portfolio company Rinascimento 5)
- International reach increase, thanks to Enry’s Island Local Companies
- Add 12x to 36x financial value within 3-5 years
- Consolidating a worldwide standard protocol for the assessment and evaluation of the startups, based on Enry’s Model intellectual property (IP)
At the forefront of the industry, Enry’s Island is the first Incubation & Acceleration Metaverse (# 1 incubator & accelerator in Italy, & # 6 in Europe according to Crunchbase Q4/2021), with local companies in US, UK, Italy, Spain, Ireland, Africa, a global community of more than 800 stakeholders who include entrepreneurs, investors, and professionals and 30 startups, thoroughly assessed and evaluated based on Enry’s Model, the patented intellectual property the whole organization, processes and tool of Enry’s Island is based on. The Enry’s Model is also part of the “Enry’s Theory” manual of business management, published by MacGraw-Hill.
About LDA Capital
LDA Capital is a global alternative investment group with expertise in cross border transactions worldwide. Our team has dedicated their careers to international & cross border opportunities having collectively executed over 250 transactions in both the public and private middle markets across 43 countries with aggregate transaction values of over US$11 billion. For more information please visit: www.ldacap.com; For inquires please email: info@ldacap.com.
About Enry’s Island
- 15 years of experience in the management of very early stage startups, with a mortality rate of only 10% (against 90% which is the industry average)
- 12-month incubation and acceleration programs, totally customized to the needs of startups, with investments of € 200k in operational services (not just mentorship)
- Proprietary patent, Enry's Model, which allows for the evaluation of company performance and value; Enry's Model is also the subject of a McGrawHill manual (which, in view of its success in Europe, has been translated for the US market);
- Explosive scale up in the last 3 years, going from 8 to 25 companies, from €2M to €40M in portfolio value, from a community of 30 to 800 stakeholders;
- full remote and totally distributed organization, which has allowed Enry’s Island to grow during the last 2 years of pandemic;
- A revolutionary corporate architecture, which includes local companies in Ita, US, UK, Africa, Ibiza, Ireland and upcoming openings in the Far East, that do not replicate, but specialize and scale the different EI best practices in the different countries.
- High information symmetry, given that the whole EI community uses a revolutionary Saas platform (hui.land), which guarantees efficiency and effectiveness in business management and business risk containment; HUI provides KPIs to all internal and external stakeholders, allowing investors to invest directly in target companies through HUI (thanks to crowdfunding campaigns in Europe, US and Canada), directly through HUI;
- A revolutionary vision and management of space, both physical (having eliminated any physical location, as if it were in a DAO, but using a network of hosts with ideal characteristics for remote working in places with a high quality of life, such as villages, natural areas) and metaverse space (EI has started investing in the metaverse, building its first building in Cryptovoxels and having launched the first investor day entirely in metaverse https://www.cryptovoxels.com/parcels/7328)
Visit www.enrysisland.com and discover why Enry’s Island has ignited interest from all over the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005729/en/
Contact information
Investor relations:
Enry’s Island - Benefit Company
Gabriele Vedani
Investor Relations Manager
gabriele.vedani@enrysisland.com
0039 335 6625055
website: enrysisland.com
website: metaverse.enrysisland.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
